Belgium· BE-AMP-SAM555822-00
Givlaari 189 mg/ml
A givosiran product containing givosiran sodium, registered in Belgium by Alnylam Netherlands. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Givosiran is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AX16 (givosiran), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Givosiran · ATC A16AX16
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Givosiran Sodium
- Manufacturer
- Alnylam Netherlands
- Country
- Belgium (BE)
- ATC code
- A16AX16
- ATC class
- Givosiran
- Defined daily dose
- 5.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4131793
- be_apb7730799
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
105 interactions on record for givosiran.
Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Givosiran · interactions on record
105 records
- 24 severe
- 81 moderate
Most severe, free to view
- EliglustatA16AX10severe
- TemsirolimusL01EG01severe
- EverolimusL01EG02severe
- SirolimusL01EG04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Givosiran in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4bbb7746-9eec-4edb-affb-8295d15f8352 GET /v1/drugs/4bbb7746-9eec-4edb-affb-8295d15f8352?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Givlaari 189 mg/ml",
"name_fr": "Givlaari 189 mg/ml",
"name_nl": "Givlaari 189 mg/ml",
"amp_code": "SAM555822-00",
"strengths": [
"189.0000"
],
"pack_count": 1,
"substances": [
"Givosiran Sodium",
"Givosiran",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Givosiran",
"authorisation_numbers": [
"EU/1/20/1428/001"
]
}See everything about givosiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.